Active, not recruitingPhase 2NCT02952508

Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom

Studying B-cell chronic lymphocytic leukemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Cellectar Biosciences, Inc.
Principal Investigator
Jarrod Longcor
Cellectar Biosciences
Intervention
Iopofosine I 131 single dose(drug)
Enrollment
120 enrolled
Eligibility
18 years · All sexes
Timeline
2017 – 2027

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02952508 on ClinicalTrials.gov

Other trials for B-cell chronic lymphocytic leukemia

Additional recruiting or active studies for the same condition.

See all trials for B-cell chronic lymphocytic leukemia →

← Back to all trials